{"pmid":32439309,"title":"[Narrative review of the immune response against coronavirus: An overview, applicability for SARS-COV-2, and therapeutic implications].","text":["[Narrative review of the immune response against coronavirus: An overview, applicability for SARS-COV-2, and therapeutic implications].","The new coronavirus (SARS-CoV-2) that causes a severe acute respiratory syndrome emerges in Wuhan, China, in December 2019. It produces the aforementioned disease due to coronavirus 2019 (COVID-19), and has led to a declaration of a world public health emergency by the World Health Organisation. This new SARS-CoV-2 virus could share characteristics and an immune response similar to those described for other coronavirus. Given its activity on the interferon pathway, and the manner in which it dysregulates innate immunity, the use of treatments directed at modulating or containing this could be of interest. A narrative review was made of the current evidence about immunity against coronavirus and its applicability to SARS-CoV-2. The physiopathogenesis is also described, along with the underlying leucocyte activity, with the intention of clarifying the possible usefulness of inflammatory biomarkers and the development of personalised treatments.","An Pediatr (Barc)","Garcia-Salido, Alberto","32439309"],"abstract":["The new coronavirus (SARS-CoV-2) that causes a severe acute respiratory syndrome emerges in Wuhan, China, in December 2019. It produces the aforementioned disease due to coronavirus 2019 (COVID-19), and has led to a declaration of a world public health emergency by the World Health Organisation. This new SARS-CoV-2 virus could share characteristics and an immune response similar to those described for other coronavirus. Given its activity on the interferon pathway, and the manner in which it dysregulates innate immunity, the use of treatments directed at modulating or containing this could be of interest. A narrative review was made of the current evidence about immunity against coronavirus and its applicability to SARS-CoV-2. The physiopathogenesis is also described, along with the underlying leucocyte activity, with the intention of clarifying the possible usefulness of inflammatory biomarkers and the development of personalised treatments."],"journal":"An Pediatr (Barc)","authors":["Garcia-Salido, Alberto"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32439309","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.anpedi.2020.04.016","keywords":["covid-19","coronavirus","immunity","inmunidad","sars-cov-2"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667535119521415168,"score":9.490897,"similar":[{"pmid":32267987,"title":"Immune responses and pathogenesis of SARS-CoV-2 during an outbreak in Iran: Comparison with SARS and MERS.","text":["Immune responses and pathogenesis of SARS-CoV-2 during an outbreak in Iran: Comparison with SARS and MERS.","The beginning of 2020 has seen the emergence of COVID-19, an outbreak caused by a novel coronavirus, SARS-CoV-2, an important pathogen for humans. There is an urgent need to better understand this new virus and to develop ways to control its spread. In Iran, the first case of the COVID-19 was reported after spread from China and other countries. Fever, cough, and fatigue were the most common symptoms of this virus. In worldwide, the incubation period of COVID-19 was 3 to 7 days and approximately 80% of infections are mild or asymptomatic, 15% are severe, requiring oxygen, and 5% are critical infections, requiring ventilation. To mount an antiviral response, the innate immune system recognizes molecular structures that are produced by the invasion of the virus. COVID-19 infection induces IgG antibodies against N protein that can be detected by serum as early as day 4 after the onset of disease and with most patients seroconverting by day 14. Laboratory evidence of clinical patients showed that a specific T-cell response against SARS-CoV-2 is important for the recognition and killing of infected cells, particularly in the lungs of infected individuals. At present, there is no specific antiviral therapy for COVID-19 and the main treatments are supportive. In this review, we investigated the innate and acquired immune responses in patients who recovered from COVID-19, which could inform the design of prophylactic vaccines and immunotherapy for the future.","Rev Med Virol","Rokni, Mohsen","Ghasemi, Vida","Tavakoli, Zahra","32267987"],"abstract":["The beginning of 2020 has seen the emergence of COVID-19, an outbreak caused by a novel coronavirus, SARS-CoV-2, an important pathogen for humans. There is an urgent need to better understand this new virus and to develop ways to control its spread. In Iran, the first case of the COVID-19 was reported after spread from China and other countries. Fever, cough, and fatigue were the most common symptoms of this virus. In worldwide, the incubation period of COVID-19 was 3 to 7 days and approximately 80% of infections are mild or asymptomatic, 15% are severe, requiring oxygen, and 5% are critical infections, requiring ventilation. To mount an antiviral response, the innate immune system recognizes molecular structures that are produced by the invasion of the virus. COVID-19 infection induces IgG antibodies against N protein that can be detected by serum as early as day 4 after the onset of disease and with most patients seroconverting by day 14. Laboratory evidence of clinical patients showed that a specific T-cell response against SARS-CoV-2 is important for the recognition and killing of infected cells, particularly in the lungs of infected individuals. At present, there is no specific antiviral therapy for COVID-19 and the main treatments are supportive. In this review, we investigated the innate and acquired immune responses in patients who recovered from COVID-19, which could inform the design of prophylactic vaccines and immunotherapy for the future."],"journal":"Rev Med Virol","authors":["Rokni, Mohsen","Ghasemi, Vida","Tavakoli, Zahra"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32267987","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1002/rmv.2107","keywords":["2019-ncov disease","b cell","covid-19","sars-cov-2","t cell","coronavirus","immunity"],"locations":["Iran","China","Iran"],"countries":["China","Iran, Islamic Republic of"],"countries_codes":["CHN|China","IRN|Iran, Islamic Republic of"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138491888599040,"score":208.07318},{"pmid":32464098,"title":"The Innate Immune System: Fighting on the Front Lines or Fanning the Flames of COVID-19?","text":["The Innate Immune System: Fighting on the Front Lines or Fanning the Flames of COVID-19?","The coronavirus disease 2019 (COVID-19) pandemic caused by SARS-CoV-2 has had devastating global impacts and will continue to have dramatic effects on public health for years to come. A better understanding of the immune response to SARS-CoV-2 will be critical for the application and development of therapeutics. The degree to which the innate immune response confers protection or induces pathogenesis through a dysregulated immune response remains unclear. In this review, we discuss what is known about the role of the innate immune system during SARS-CoV-2 infection, suggest directions for future studies, and evaluate proposed COVID-19 immunomodulating therapeutics.","Cell Host Microbe","McKechnie, Julia L","Blish, Catherine A","32464098"],"abstract":["The coronavirus disease 2019 (COVID-19) pandemic caused by SARS-CoV-2 has had devastating global impacts and will continue to have dramatic effects on public health for years to come. A better understanding of the immune response to SARS-CoV-2 will be critical for the application and development of therapeutics. The degree to which the innate immune response confers protection or induces pathogenesis through a dysregulated immune response remains unclear. In this review, we discuss what is known about the role of the innate immune system during SARS-CoV-2 infection, suggest directions for future studies, and evaluate proposed COVID-19 immunomodulating therapeutics."],"journal":"Cell Host Microbe","authors":["McKechnie, Julia L","Blish, Catherine A"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32464098","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.chom.2020.05.009","keywords":["covid-19","sars-cov-2","complement","cytokines","innate immune response","myeloid cells","natural killer cells"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668079521216069632,"score":201.64111},{"pmid":32376901,"pmcid":"PMC7201395","title":"Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages.","text":["Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages.","The COVID-19 pandemic caused by infection with SARS-CoV-2 has led to more than 200,000 deaths worldwide. Several studies have now established that the hyperinflammatory response induced by SARS-CoV-2 is a major cause of disease severity and death in infected patients. Macrophages are a population of innate immune cells that sense and respond to microbial threats by producing inflammatory molecules that eliminate pathogens and promote tissue repair. However, a dysregulated macrophage response can be damaging to the host, as is seen in the macrophage activation syndrome induced by severe infections, including in infections with the related virus SARS-CoV. Here we describe the potentially pathological roles of macrophages during SARS-CoV-2 infection and discuss ongoing and prospective therapeutic strategies to modulate macrophage activation in patients with COVID-19.","Nat Rev Immunol","Merad, Miriam","Martin, Jerome C","32376901"],"abstract":["The COVID-19 pandemic caused by infection with SARS-CoV-2 has led to more than 200,000 deaths worldwide. Several studies have now established that the hyperinflammatory response induced by SARS-CoV-2 is a major cause of disease severity and death in infected patients. Macrophages are a population of innate immune cells that sense and respond to microbial threats by producing inflammatory molecules that eliminate pathogens and promote tissue repair. However, a dysregulated macrophage response can be damaging to the host, as is seen in the macrophage activation syndrome induced by severe infections, including in infections with the related virus SARS-CoV. Here we describe the potentially pathological roles of macrophages during SARS-CoV-2 infection and discuss ongoing and prospective therapeutic strategies to modulate macrophage activation in patients with COVID-19."],"journal":"Nat Rev Immunol","authors":["Merad, Miriam","Martin, Jerome C"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32376901","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1038/s41577-020-0331-4","topics":["Treatment","Mechanism"],"weight":1,"_version_":1666597097376317440,"score":194.90166},{"pmid":32459123,"title":"Mechanistic inferences from clinical reports of SARS-CoV-2.","text":["Mechanistic inferences from clinical reports of SARS-CoV-2.","SARS-CoV-2 was identified as the causative pathogen in an outbreak of viral pneumonia cases originating in Wuhan, China, with an ensuing rapid global spread that led it to be declared a pandemic by the WHO on March 11, 2020. Given the threat to public health posed by sequelae of SARS-CoV-2 infection, the literature surrounding patient presentation in severe and non-severe cases, transmission rates and routes, management strategies, and initial clinical trial results have become available at an unprecedented pace. In this review we collate current clinical and immunologic reports, comparing these to reports of previous coronaviruses to identify mechanisms driving progression to severe disease in some patients. In brief, we propose a model wherein dysregulated type I interferon signalling leads to aberrant recruitment and accumulation of innate immune lineages in the lung, impairing establishment of productive adaptive responses, and permitting a pathologic pro-inflammatory state. Finally, we extend these findings to suggest possible treatment options that may merit investigation in randomized clinical trials.","Infect Dis (Lond)","Jenkins, Meagan M","McCaw, Tyler R","Goepfert, Paul A","32459123"],"abstract":["SARS-CoV-2 was identified as the causative pathogen in an outbreak of viral pneumonia cases originating in Wuhan, China, with an ensuing rapid global spread that led it to be declared a pandemic by the WHO on March 11, 2020. Given the threat to public health posed by sequelae of SARS-CoV-2 infection, the literature surrounding patient presentation in severe and non-severe cases, transmission rates and routes, management strategies, and initial clinical trial results have become available at an unprecedented pace. In this review we collate current clinical and immunologic reports, comparing these to reports of previous coronaviruses to identify mechanisms driving progression to severe disease in some patients. In brief, we propose a model wherein dysregulated type I interferon signalling leads to aberrant recruitment and accumulation of innate immune lineages in the lung, impairing establishment of productive adaptive responses, and permitting a pathologic pro-inflammatory state. Finally, we extend these findings to suggest possible treatment options that may merit investigation in randomized clinical trials."],"journal":"Infect Dis (Lond)","authors":["Jenkins, Meagan M","McCaw, Tyler R","Goepfert, Paul A"],"date":"2020-05-28T11:00:00Z","year":2020,"_id":"32459123","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1080/23744235.2020.1769853","keywords":["covid-19","covid-19 mechanisms","covid-19 pneumonia","sars-cov-2","immune response"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1667967698981617664,"score":191.56622},{"pmid":32343415,"title":"Long-term coexistence of SARS-CoV-2 with antibody response in COVID-19 patients.","text":["Long-term coexistence of SARS-CoV-2 with antibody response in COVID-19 patients.","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causing coronavirus disease 2019 (COVID-19) has spread worldwide. Whether antibodies are important for the adaptive immune responses against SARS-CoV-2 infection needs to be determined. Here, 26 cases of COVID-19 in Jinan, China, were examined and shown to be mild or with common clinical symptoms, and no case of severe symptoms was found among these patients. Strikingly, a subset of these patients had SARS-CoV-2 and virus-specific IgG coexist for an unexpectedly long time, with two cases for up to 50 days. One COVID-19 patient who did not produce any SARS-CoV-2-bound IgG successfully cleared SARS-CoV-2 after 46 days of illness, revealing that without antibody-mediated adaptive immunity, innate immunity alone may still be powerful enough to eliminate SARS-CoV-2. This report may provide a basis for further analysis of both innate and adaptive immunity in SARS-CoV-2 clearance, especially in nonsevere cases.","J Med Virol","Wang, Bin","Wang, Li","Kong, Xianggen","Geng, Jin","Xiao, Di","Ma, Chunhong","Jiang, Xue-Mei","Wang, Pei-Hui","32343415"],"abstract":["Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causing coronavirus disease 2019 (COVID-19) has spread worldwide. Whether antibodies are important for the adaptive immune responses against SARS-CoV-2 infection needs to be determined. Here, 26 cases of COVID-19 in Jinan, China, were examined and shown to be mild or with common clinical symptoms, and no case of severe symptoms was found among these patients. Strikingly, a subset of these patients had SARS-CoV-2 and virus-specific IgG coexist for an unexpectedly long time, with two cases for up to 50 days. One COVID-19 patient who did not produce any SARS-CoV-2-bound IgG successfully cleared SARS-CoV-2 after 46 days of illness, revealing that without antibody-mediated adaptive immunity, innate immunity alone may still be powerful enough to eliminate SARS-CoV-2. This report may provide a basis for further analysis of both innate and adaptive immunity in SARS-CoV-2 clearance, especially in nonsevere cases."],"journal":"J Med Virol","authors":["Wang, Bin","Wang, Li","Kong, Xianggen","Geng, Jin","Xiao, Di","Ma, Chunhong","Jiang, Xue-Mei","Wang, Pei-Hui"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32343415","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1002/jmv.25946","keywords":["covid-19","igg","sars-cov-2","antibody","immunity"],"locations":["Jinan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138495776718848,"score":189.61461}]}